Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 17Terminated 4Withdrawn 2Active not recruiting 2Recruiting 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 11Lymphoid 6Myeloid 4Plasma cell 3Other solid neoplasm 3Breast 2Sarcoma 1Other neoplasm 1NET 1Head & Neck 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Melanoma 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 65Nivolumab 58Ipilimumab 32Cyclophosphamide 22Specimen Handling 16Magnetic Resonance Spectroscopy 15Biopsy 15relatlimab 13cemiplimab 13fludarabine 12Opdualag 12binimetinib 10Blood Specimen Collection 10aldesleukin 9Radiosurgery 9encorafenib 8Interleukin-2 8atezolizumab 7Immunotherapy 7tebentafusp 6mogamulizumab 6fludarabine phosphate 6Temozolomide 6Surgical Procedures, Operative 6Paclitaxel 6Immunoglobulin G 6CTLA-4 Antigen 6Radiotherapy 5Disulfides 5Bevacizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Sirolimus × Dermatologic × Clear all
NCT05896839 2026-05-13

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
16 enrolled
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡